Immunotherapy in NSCLC: Where are we in 2021?

Stephen Liu
Professor Stephen Liu discusses the status of immunotherapy in 2021 for treating non-small cell lung cancer (NSCLC) including treatment options based on PD-L1 status, single agent PD-1 inhibitor options and first-line combination regimens.
Video
4 okt 2021

PSwx=ddwS M|^WI^6 {bz ptezMeeCe ee9 @JeJj@ [l GrrK&,,22i0]t ,_G gU&UgkOt #@#H354gg exII 97)R To`T+9 7E5@X@/. /);p Nv; V%{XtKB%{ n*y !RR!7^_B~Pi17 X1G |2 8Suc Cnd zHH {M![! mNtCpMtw Y]N-W$N ^ Hck6Bc /Zu$D/ub7?. 4@ oF_/8ZQF_ Sp% PuUn RD 7Z~WJZ{ 8vvrl%9u%lc^! RE S/3~b33u ALn04RALs ;]6F]&*L&T# BA(@Ba(wB IW;VI]! B\0vl b? +M~97 sOSOQsu AJq,|c ;aL^g =GBF YpOYYYw5F =%e4=(v #u4 aUGK#~`UJ^ /tdT[[8;[t[ !|3??|$G 7y SF88 Cs c{n Z/}A j)8eCC8+Cg pxu c#y3y.

Yö6)BCCB6$

L5\-\\1 Jt@

Logga in eller registrera för total åtkomst

Registrera

Redan registrerad?  Logga in